Read Time: 3 minutesTech Topics In This Article: Security tech, Georgia startupsPrevent. Predict. Protect.Law enforcement groups, national security agencies, and first responders all have tools to react to threats. But the data they need to prevent crime is often found in disparate and hard-to-find locations.That’s where the security-focused startup Bravo Foxtrot hopes to make its mark. The company, based out of Canton, Georgia, is “taking raw intelligence and turning it into actionable intelligence,” said Founder Brandon Puhlman. The goal is to provide law enforcement officials and first responders with the investigative tools to predict, prevent, and respond to criminal activities accurately, efficiently, and safely.Agencies can speak to the platform in plain English about a real-time criminal investigation they are working on and gather information that can be more easily shared across jurisdictions who are involved in an active case.But the AI-powered platform is not designed to give law enforcement agencies blanket access to information

HUNTINGTON, N.Y., Jan. 27, 2025 /PRNewswire/ -- A newly published paper in the Global Journal of Addiction Rehabilitation Medicine further expands on the U.S. Surgeon General's advisory, linking frequent alcohol consumption and hangovers to chronic systemic inflammation and heightened cancer risk. Fortunately, Sen-Jam Pharmaceutical's innovative therapeutic, SJP-001, is specifically designed to target this inflammatory pathway, offering a groundbreaking solution to mitigate alcohol-induced health risks

HUNTINGTON, N.Y., Jan. 22, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a leader in innovative solutions targeting inflammation and metabolic health, proudly announces a financial and strategic investment from 5 Horizons Capital. Horizon, as the lead investor for the Phase 2 clinical trial of SJP-001, Sen-Jam's flagship therapeutic, is paving the way for innovation in collaboration with Novotech, a global full-service clinical Contract Research Organization (CRO), while actively seeking follow-on investments to further accelerate this groundbreaking initiative.The SJP-001 clinical trial, which recently received ethics approval in Australia, is designed to evaluate the therapeutic's efficacy in mitigating inflammation and promoting metabolic health, specifically targeting relief from dietary and alcohol-induced overindulgence. With the support of 5 Horizons Capital, Sen-Jam is poised to execute a robust trial strategy in collaboration with Novotech, renowned for its expertise in early-phase clinical trials.Jim Iversen, Co-Founder and CEO of Sen-Jam Pharmaceutical, stated, "We are thrilled to welcome 5 Horizons Capital as a financial and strategic partner to our team, on our journey to revolutionize inflammation care. Their investment and expertise in advancing clinical-stage therapies will enable us to bring SJP-001 closer to patients worldwide. With Novotech's excellence in trial management and 5 Horizons' visionary support, we are one step closer to transforming how the world addresses metabolic health and inflammation."Aaron Ray, Managing Director of 5 Horizons Capital, commented, "As the lead investor in Sen-Jam's Phase 2 clinical trial for SJP-001, we are proud to be part of this community that has the potential to redefine how inflammation is treated globally